Clinical Trial Update: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS [Phase 2]

View source ↗

Summary

A Phase 2 trial compares durvalumab plus tremelimumab with chemotherapy against pembrolizumab plus chemotherapy in metastatic non-squamous non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Pembrolizumab (pembrolizumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: ACTIVE_NOT_RECRUITING